IQ4I Research & Consultancy published a new report on “Congestive Heart Failure (CHF)- Pipeline...

Congestive Heart Failure

IQ4I Research & Consultancy Pvt. Ltd.

Congestive Heart Failure

Pipeline Analysis

� REPORT DESCRIPTION

� INTRODUCTION� Causes & Symptoms

� Diagnosis

� Classification

� Compensatory mechanisms

� Unmet needs

� EPIDEMIOLOGY� Prevalence

� Incidence

� Hospitalizations

� GENETHERAPY� Pipeline

� Competitive landscape

� STEMCELL THERAPY� Pipeline


� RNA BASED THERAPEUTICS� mi-RNA

� m-RNA

� Pipeline


CONTENTS

� Re-admissions

� MARKET DATA� Forecasting model

� Market dynamics

� Market sizing

� Cost burden

� PIPELINE ANALYSIS� Development stage

� Modalities

� Leading players

� Innovative approaches

� Associated targets


� DRUGS (small molecules, recombinant proteins, growth factors)

� Pipeline


� HOT TARGETS IN RESEARCH

� MAJOR PLAYERS� Company Profiles

� Overview, Pipeline & Deals

� REFERENCES

Confidential

� “Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensiveinsight on the various drugs being developed for the treatment of CHF. Thereport covers all the drugs being developed in various development phases(Discovery to Phase 2 clinical). The pipeline focuses on disease modification andincludes pharmacologic drugs, gene therapy, stem cell therapy and RNA-basedtherapeutics, but excludes symptom relief drugs like diuretics, acute treatments,angiotensins or thrombin inhibitors etc. The report also covers some of the hottargets in research for CHF treatments.

� This report enables Pharmaceutical /Biotech companies, Academic institutes,

REPORT DESCRIPTION

� This report enables Pharmaceutical /Biotech companies, Academic institutes,Individual researchers, Investors, Medical technology companies, Serviceproviders and other associated stake holders to identify and analyze the availablelicensing/collaborative opportunities in the CHF Drug market. The report alsoprovide strategic insights on medicines that are likely to have an impact on CHFtreatment space and potentially alter standards of care in CHF in the foreseeablefuture.

� Current therapies focuses only to slow down the progression of the disease asmore number of molecules are symptom relieving drugs, hence it provides atremendous opportunity for upcoming therapies specific to CHF such as gene-based, stem cell-based and miRNA-based therapies, which reverses diseasecourse and reduce the number of cardiac events.

CONGESTIVE HEART FAILURECONGESTIVE HEART FAILURE

INTRODUCTION

INTRODUCTIONINTRODUCTIONDefinition: Congestive heart failure (CHF) is a condition which is characterized by the inability

of heart muscle to pump out enough oxygen-rich blood and maintain adequate circulation of

blood in tissues of the body.

Definition: Congestive heart failure (CHF) is a condition which is characterized by the inability

of heart muscle to pump out enough oxygen-rich blood and maintain adequate circulation of

blood in tissues of the body.

CONGESTIVE HEART FAILURE (CHF)

Confidential

CHF - DIAGNOSIS

BLOOD TEST

ELECTROCHEST

CHF DIAGNOSIS

ELECTROCARDIOG

RAM

NUCLEAR IMAGING

STRESS TEST

CHEST RADIOGR

APHY

Confidential

CLINICAL CLASSIFICATION OF

HEART FAILURE

BASED ON

COURSE OF DISEASE

BASED ON

OUTPUT

BASED ON

LOCATION

BASED ON

IMPAIRED FUNCTION

CHF - CLASSIFICATION

Systolic Failure

Diastolic Failure

Acute Heart Failure

Chronic Heart

Failure

Left-sided Heart

Failure

Right-sided Heart

Failure

Low-output Heart

Failure

High-output Heart

Failure

Biventricular Heart

Failure

Confidential


EPIDEMIOLOGY

North America:X MN

Europe: X MN

Asia: X MN

{MN: Million}

CHF - GLOBAL PREVALENCE

* Population living with heart failure in prominent regions across the globe, 2013 estimates

Australia: X MN

Middle East: X MN

Latin America:X MN

World: X million CHF cases

Africa & ROWX MN

Confidential


MARKET DATA

CHF - GLOBAL MARKET SIZING

Global CHF Drugs Market Global CHF Drugs Market by Region

Mar

ket

Siz

e ($

Bil

lio

n)

Fig 6 Fig 7

• The global CHF market is estimated to be $XX billion in 2013 and is expected to grow at a CAGR of XX% from

2013 to 2018 to reach $XX billion by 2018

• The market growth is attributed to technological advancements, which led to emergence of novel therapeutics,

expansion in number of heart centres, increasing incidence of cardiovascular diseases, alteration in lifestyle and

high unmet needs

Year

Mar

ket

Siz

e ($

Bil

lio

n)

Year

Confidential


PIPELINE ANALYSIS

CHF - PIPELINE BY DEVELOPMENT STAGE

No

: of

Mo

lecu

les

Fig 9

• Pipeline analysis reveals that there are XX molecules in various stages of pipeline (focused only on

Discovery, Pre-clinical, Phase I & Phase II candidates)

• The preclinical stage commanded the largest share with around XX molecules, followed by phase II with

around XX molecules

No

: of

Mo

lecu

les

Confidential

CHF – PIPELINE BY MODALITIES

Fig 10

Drugs

Genetherapy

Confidential

Stem cell therapy

RNA based therapy

CHF – PIPELINE BY LEADING PLAYERS

Fig 11

No.

of

mo

lecu

les

Confidential

No.

of

mo

lecu

les


GENETHERAPY

Molecule Company Phase Target Comments

MydicarCelladon

CorpoartionPhase II b SERCA2A

Apr-2014, it has been granted grantedbreakthrough therapy designation by FDA. Goal of

this treatment is to restore the SERCA2a levels in

HF. Celladon believes that, if EMA conditions

(safety in 205-230 patients with substantial and

highly significant treatment effect and no untoward

effects are met, a PIII trial may not be required for

filing in Europe.

XX XX XX XX XX

GENE THERAPY PIPELINE

XX XX XX XX XX

XX XX XX XX XX

Confidential


STEMCELL THERAPY

Molecule Company Phase Comments

XX XX XX XX

XX XX XX XX

XX XX XX XX

XX XX XX XX

STEM CELL THERAPY PIPELINE

Confidential


RNA BASED THERAPEUTICS

RNA THERAPEUTICS PIPELINE DATA

Molecule Company Phase Comments

XX XX XX XX

XX XX XX XX

XX XX XX XX

XX XX XX XX

Confidential


DRUGS (small molecules, recombinant proteins, Growth factors)

Molecule Company Phase Target Comments

XX XX XX XX XX

XX XX XX XX XX

XX XX XX XX XX

XX XX XX XX XX

DRUGS PIPELINE

XX XX XX XX XX

Confidential


MAJOR PLAYERS

CHF KEY PLAYERS - HEADQUARTERS

Moderna therapeutics

Miragen therapeutics

Nanocor

ONO

pharmaceuticals

Celladon corporation

Juventas therapeutics

Bayer AG

GSK

Merck & Co

Confidential

Coretherapix

Nanocor therapeutics

Bioheart

Confidential

Co

Bayer is an innovative research company founded in the year 1863 and is headquartered in Germany. The

company mainly focuses on R&D activities for innovative treatment for various diseases with high unmet

medical need. With new approaches in oncology, cardiovascular diseases and gynaecological therapies Bayer

healthcare seeks to become an innovative leader. In 2013, the company revenue was accounted for $51.49

billion.

COMPANY-BAYER AG

OVERVIEW

PIPELINE

Chronic heart failureBAY-1067197

Discovery Preclinical Phase I Phase II

XXXX

XXXX

XXXX

XXXX

XXXX

XXXX

XXXX

XXXX

DISCLAIMERIQ4I strategic analysis services are limited publications containing valuable market

information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that IQ4I strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties. Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

IQ4I does not endorse any vendor, product or service depicted in its research publications. IQ4I strategic analysis publications consist of the opinions of IQ4I' research and should not be construed as statements of fact. IQ4I disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

IQ4I takes no responsibility for any incorrect information supplied to us by manufacturers or users. or users.

All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of their owner.

No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.

Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording or otherwise, without the permission of the publisher is prohibited.

For information regarding permission, contact: Tel: +91 80 60500229Email: [email protected]

Confidential

THANK YOUTHANK YOUTHANK YOUTHANK YOU

IQ4I Research & Consultancy published a new report on “Congestive Heart Failure (CHF)- Pipeline...

Healthcare

Transcript of IQ4I Research & Consultancy published a new report on “Congestive Heart Failure (CHF)- Pipeline...